Biotech | 09 December 2025
AL-S Pharma shows promising Phase 2 results for its therapy in ALS treatment
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
The new Bioprocess Design Center will serve as a cutting-edge scale-up hub for biologics and vaccine manufacturing
Diversifying its portfolio to include late-phase antiviral agent
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Several technologies for hemoglobinopathies are being transferred to commercial partners
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
The new site enables end-to-end production of viral vector gene therapies
Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031
Subscribe To Our Newsletter & Stay Updated
